Skip to main content
. 2021 Aug 20;41(5):516–524. doi: 10.1097/JCP.0000000000001465

FIGURE 3.

FIGURE 3

Odds ratios (95% CI) for a ≥2-point improvement in the MADRS item scores during the double-blind treatment phase. a Includes patients who had their dose reduced because of tolerability issues. Notes: MADRS items are rated on a scale of 0 to 6 where 0 indicates no abnormality and 6 indicates severe. The reduced sleep item was not assessed at the 4-hour post–first dose time point.